Generic Name and Formulations:
Leflunomide 10mg, 20mg, 100mg; tabs.
Indications for ARAVA:
Active rheumatoid arthritis.
Arava-associated hepatotoxicity and myelosuppression (low-risk): give loading dose of 100mg once daily for 3 days; then 20mg daily thereafter; (high-risk): give 20mg once daily without loading dose. Max 20mg/day. If not well tolerated, consider reducing to 10mg daily; monitor closely. Perform accelerated drug elimination procedure with cholestyramine and/or activated charcoal after stopping therapy.
Severe hepatic impairment. Concomitant teriflunomide. Pregnancy.
Pre-existing hepatic disease or ALT>2xULN: not recommended. Monitor liver function (esp. ALT) and blood (WBCs, platelets, hemoglobin, HCT) at baseline, then monthly for 1st six months; then every 6–8 weeks. If ALT elevations >3xULN, interrupt and evaluate; if likely leflunomide-induced, perform accelerated drug elimination procedure and monitor LFTs weekly until normalized; if unlikely, may consider resuming therapy. Obtain (–) pregnancy test before starting therapy. Females of reproductive potential should use effective contraception during treatment and during an accelerated drug elimination procedure after stopping treatment (see full labeling). Test and treat, if positive for active or latent TB infection prior to starting therapy. Renal impairment. Monitor BP. Severe immunodeficiency, bone marrow dysplasia, severe uncontrolled infections, nursing mothers: not recommended.
See Contraindications. Concomitant methotrexate, other immunosuppressants: monitor for hepatic or hematologic toxicity monthly. Caution with rifampin, and with other hepatotoxic drugs. May potentiate CYP2C8 (eg, paclitaxel, pioglitazone, repaglinide) or OAT3 (eg, cefaclor, cimetidine, ciprofloxacin) substrates, oral contraceptives; monitor and adjust dose as needed. May antagonize CYP1A2 (eg, alosetron, duloxetine, theophylline) substrates; monitor and adjust dose as needed. Consider reducing dose of OATP or BCRP substrates, esp. statins (limit rosuvastatin dose to 10mg/day). Concomitant live vaccines: not recommended; consider leflunomide long half-life before vaccination after stopping therapy. Monitor warfarin.
DMARD (pyrimidine synthesis inhibitor).
Diarrhea, elevated liver enzymes, alopecia, rash, respiratory infection, hypertension, headache, GI upset; rare: hepatotoxicity (may be fatal), interstitial lung disease, immunosuppression (possible sepsis), bone marrow suppression, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, peripheral neuropathy: stop therapy and perform drug elimination procedure.
Tabs 10mg, 20mg—30; 100mg—blister pack (1 x 3)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders
- Mortality Rates for Substance Use Disorders, Intentional Injuries Vary Widely By Country
- Facial Emotion Recognition Differentiates Behavioral Variant Frontotemporal Dementia From MDD
- The Challenge of Helping Uninsured Patients While Protecting Practice Finances
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed